JP2003525902A - 耐性および依存症を治療するための代謝共役型グルタミン酸受容体アンタゴニスト - Google Patents

耐性および依存症を治療するための代謝共役型グルタミン酸受容体アンタゴニスト

Info

Publication number
JP2003525902A
JP2003525902A JP2001564765A JP2001564765A JP2003525902A JP 2003525902 A JP2003525902 A JP 2003525902A JP 2001564765 A JP2001564765 A JP 2001564765A JP 2001564765 A JP2001564765 A JP 2001564765A JP 2003525902 A JP2003525902 A JP 2003525902A
Authority
JP
Japan
Prior art keywords
addiction
mglur5
product
substance
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001564765A
Other languages
English (en)
Japanese (ja)
Inventor
コルシ，マウロ
コンクエット，フランセス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9887294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2003525902(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2003525902A publication Critical patent/JP2003525902A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fertilizers (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
JP2001564765A 2000-03-09 2001-03-09 耐性および依存症を治療するための代謝共役型グルタミン酸受容体アンタゴニスト Pending JP2003525902A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0005700.0 2000-03-09
GBGB0005700.0A GB0005700D0 (en) 2000-03-09 2000-03-09 Therapy
PCT/GB2001/001058 WO2001066113A1 (en) 2000-03-09 2001-03-09 Metabotropic glutamate receptor antagonists for treating tolerance and dependency

Publications (1)

Publication Number Publication Date
JP2003525902A true JP2003525902A (ja) 2003-09-02

Family

ID=9887294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001564765A Pending JP2003525902A (ja) 2000-03-09 2001-03-09 耐性および依存症を治療するための代謝共役型グルタミン酸受容体アンタゴニスト

Country Status (16)

Country Link
US (1) US20030195139A1 (cg-RX-API-DMAC10.html)
EP (1) EP1267869B1 (cg-RX-API-DMAC10.html)
JP (1) JP2003525902A (cg-RX-API-DMAC10.html)
CN (1) CN1427720A (cg-RX-API-DMAC10.html)
AT (1) ATE267013T1 (cg-RX-API-DMAC10.html)
AU (1) AU783869B2 (cg-RX-API-DMAC10.html)
CA (1) CA2402341A1 (cg-RX-API-DMAC10.html)
DE (1) DE60103384T2 (cg-RX-API-DMAC10.html)
DK (1) DK1267869T3 (cg-RX-API-DMAC10.html)
ES (1) ES2220727T3 (cg-RX-API-DMAC10.html)
GB (1) GB0005700D0 (cg-RX-API-DMAC10.html)
NZ (1) NZ521228A (cg-RX-API-DMAC10.html)
PT (1) PT1267869E (cg-RX-API-DMAC10.html)
SE (1) SE1267869T5 (cg-RX-API-DMAC10.html)
TR (1) TR200401862T4 (cg-RX-API-DMAC10.html)
WO (1) WO2001066113A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529975A (ja) * 2017-07-31 2020-10-15 ノバルティス アーゲー コカイン使用の低減又はコカイン使用再燃の予防におけるマボグルラントの使用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0314192A (pt) * 2002-09-10 2005-07-26 Novartis Ag Antagonistas de receptores de mglu para tratamento de distúrbios associados com receptores de mglu incluindo vìcio e depressão
ES2819303T3 (es) 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
WO2006121919A2 (en) * 2005-05-05 2006-11-16 Massachusetts Institute Of Technology Methods of treating obsessive compulsive disorder
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007035823A2 (en) * 2005-09-20 2007-03-29 Molecular Neuroimaging, Llc Partial mglur5 antagonists and methods of use thereof
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
DK2083811T3 (en) 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
US20130123254A1 (en) * 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
GB201312800D0 (en) 2013-07-17 2013-08-28 Heptares Therapeutics Ltd mGlu5 modulators
AU2018310882C1 (en) 2017-07-31 2021-12-09 Novartis Ag Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
JP7620694B2 (ja) * 2020-07-17 2025-01-23 ノバルティス アーゲー オピオイド使用の低減用医薬品及びオピオイド禁断の促進用医薬品
CA3204360A1 (en) * 2020-12-14 2022-06-23 Novartis Ag Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5543698A (en) * 1994-09-27 1996-08-06 Allen-Bradley Company, Inc. Method and apparatus used with AC motor for detecting unbalance
GB9609976D0 (en) * 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
US6294355B1 (en) * 1997-03-14 2001-09-25 The Johns Hopkins University School Of Medicine Synaptic activation protein compositions and method
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6057368A (en) * 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
ID29095A (id) * 1998-10-02 2001-07-26 Novartis Ag Cs Antagonis mglur5 untuk pengobatan rasa sakit dan kegelisahan
TW593241B (en) * 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
WO2000069816A1 (en) * 1999-05-17 2000-11-23 Eli Lilly And Company Metabotropic glutamate receptor antagonists
US6666209B2 (en) * 2001-02-20 2003-12-23 3M Innovative Properties Company Method and system of calibrating air flow in a respirator system

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529975A (ja) * 2017-07-31 2020-10-15 ノバルティス アーゲー コカイン使用の低減又はコカイン使用再燃の予防におけるマボグルラントの使用
JP2023109917A (ja) * 2017-07-31 2023-08-08 ノバルティス アーゲー コカイン使用の低減又はコカイン使用再燃の予防におけるマボグルラントの使用
US11878001B2 (en) 2017-07-31 2024-01-23 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
JP7645037B2 (ja) 2017-07-31 2025-03-13 ノバルティス アーゲー コカイン使用の低減又はコカイン使用再燃の予防におけるマボグルラントの使用

Also Published As

Publication number Publication date
CN1427720A (zh) 2003-07-02
AU3763401A (en) 2001-09-17
SE1267869T3 (cg-RX-API-DMAC10.html) 2004-08-31
AU783869B2 (en) 2005-12-15
ATE267013T1 (de) 2004-06-15
NZ521228A (en) 2004-04-30
HK1053262A1 (en) 2003-10-17
CA2402341A1 (en) 2001-09-13
WO2001066113A1 (en) 2001-09-13
DE60103384T2 (de) 2005-06-16
US20030195139A1 (en) 2003-10-16
EP1267869A1 (en) 2003-01-02
PT1267869E (pt) 2004-10-29
ES2220727T3 (es) 2004-12-16
GB0005700D0 (en) 2000-05-03
EP1267869B1 (en) 2004-05-19
TR200401862T4 (tr) 2004-10-21
DE60103384D1 (de) 2004-06-24
DK1267869T3 (da) 2004-09-20
SE1267869T5 (cg-RX-API-DMAC10.html) 2004-09-07

Similar Documents

Publication Publication Date Title
EP1267869B1 (en) Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance
Cheron et al. Drug addiction: from bench to bedside
Young et al. Excitatory amino acid receptors in the brain: membrane binding and receptor autoradiographic approaches
Shoblock et al. Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement
Kolachala et al. Blockade of adenosine A2B receptors ameliorates murine colitis
Michalak et al. Alcohol dependence ń neurobiology and treatment
Kintz et al. Exercise modifies α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor expression in striatopallidal neurons in the 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine‐lesioned mouse
Landoni et al. Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves
Castané et al. Attenuation of nicotine-induced rewarding effects in A2A knockout mice
Baldo Current research in pathophysiology of opioid-induced respiratory depression, neonatal opioid withdrawal syndrome, and neonatal antidepressant exposure syndrome
Huang et al. Bulleyaconitine A exerts antianxiety and antivisceral hypersensitivity effects
Budzynska et al. Effects of calcium channel antagonists on the motivational effects of nicotine and morphine in conditioned place aversion paradigm
Maggio et al. Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats
Gu et al. Activation of bitter taste receptor TAS2R4 alleviates diabetic nephropathy in mice
Berger et al. Morphine‐induced mu opioid receptor trafficking enhances reward yet prevents compulsive drug use
US20110039834A1 (en) Novel pharmaceutical compositions for optimizing substitution treatments and extending the pharmacopoeia to global treatment of addictions
Minervini et al. Punishment and reinforcement by opioid receptor agonists in a choice procedure in rats
Lee et al. Chronic cocaine administration reduces striatal dopamine terminal density and striatal dopamine release which leads to drug-seeking behaviour
Brown et al. Toll-like receptor 4 antagonists reduce cocaine-primed reinstatement of drug seeking
HK1053262B (en) Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance
Walker et al. Role of lateral hypothalamic orexin (hypocretin) neurons in alcohol use and abuse: recent advances
EP3582764B1 (en) Treatment of alcohol use disorder
Hess The Role of System XC-in Cognition: The Importance of Neuron-Astrocyte Signaling
Mhatre et al. 5-HT3 receptor antagonist ICS 205-930 alters the discriminative effects of ethanol
Akula et al. Adenosinergic system: an assorted approach to therapeutics for drug addiction

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060818

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070327